SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. William Huang discussing results from the ENVISION trial assessing primary chemoablation ...
X4 Pharmaceuticals highlights 2024 as transformative with XOLREMDI's U.S. launch, international expansion, & Phase 3 trial progress.
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Discover how Moleculin Biotech advances Annamycin's Phase 3 trial for AML treatment, with key milestones planned through 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback